The effects of Vasopressin and its analogues on the liver and its disorders in the critically ill

Current Opinion in Critical Care

Volumn 16, Issue 2, 2010, Pages 148-152

  Asfar, Pierre ^a   Radermacher, Peter ^b   Calès, Paul ^a,c   Oberti, Frédéric ^a,c  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cirrhosis; Hepatorenal syndrome; Septic shock; Splanchnic hemodynamics; Terlipressin; Variceal bleeding; Vasopressin

Indexed keywords

ALBUMIN; NORADRENALIN; PLACEBO; TERLIPRESSIN; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; ESOPHAGUS VARICES BLEEDING; FLUID RESUSCITATION; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE; ISCHEMIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; REVIEW; SEPTIC SHOCK; SPLANCHNIC BLOOD FLOW;

CRITICAL CARE; CRITICAL ILLNESS; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMANS; INTENSIVE CARE UNITS; LIVER; LIVER CIRRHOSIS; LYPRESSIN; RISK FACTORS; SHOCK, SEPTIC; VARICOSE VEINS; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 77952264203     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328335a35b     Document Type: Review

References (55)

1. Sanyal A, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008;134:1715-1728. A review on the management of complications of portal hypertension. (Pubitemid 351626956)
2. Iwakiri Y, Groszmann R. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121-S131. (Pubitemid 43303976)
3. Moreau R, Cailmail S, Lebrec D. Effects of vasopressin on haemodynamics in portal hypertensive rats receiving clonidine. Liver 1994;14:45-49. (Pubitemid 24089307)
4. Huang HC, Wang SS, Lee FY, et al. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition. J Gastroenterol Hepatol 2008; 23: e265-e269.
5. Bosch J, Bordas JM, Mastai R, et al. Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure. Hepatology 1988;8:861-865.
6. Ready JB, Robertson AD, Rector WG Jr. Effects of vasopressin on portal pressure during hemorrhage from esophageal varices. Gastroenterology 1991;100:1411-1416.
7. Iwao T, Toyonaga A, Oho K, et al. Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. J Hepatol 1996;25:491-497. (Pubitemid 26345893)
8. Kravetz D, Cummings SA, Groszmann RJ. Hyposensitivity to vasopressin in a hemorrhaged-transfused rat model of portal hypertension. Gastroenterology 1987;93:170-175. (Pubitemid 17084110)
9. Tsai YT, Lee FY, Lin HC, et al. Hyposensitivity to vasopressin in patients with hepatitis B-related cirrhosis during acute variceal hemorrhage. Hepatology 1991;13:407-412.
10. Freeman JG, Barton JR, Record CO. Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Aliment Pharmacol Ther 1988;2:361-367.
11. Lebrec D, Moreau R, Cailmail S, et al. Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol. J Hepatol 1993;17:102-107. (Pubitemid 23037986)
12. Heinemann A, Stauber RE. Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol 1996;24:739-746. (Pubitemid 26226671)
13. Oberti F, Veal N, Kaassis M, et al. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. J Hepatol 1998;29:103-111. (Pubitemid 28307989)
14. Nevens F, Van Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous noninvasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996;38:129-134. (Pubitemid 26020939)
15. Chiu KW, Sheen IS, Liaw YF. A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices. J Gastroenterol Hepatol 1990;5:549-553.
16. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, et al. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004;39:486-492. (Pubitemid 38626630)
17. Bosch J, Lebrec D, Jenkins SA. Development of analogues: successes and failures. Scand J Gastroenterol Suppl 1998;226:3-13. (Pubitemid 28212561)
18. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006: CD005162. (Pubitemid 46841333)
19. Bernard B, Valla D. Efficacy and mode of action of vasopressin in the treatment of digestive hemorrhages caused by rupture of esophageal or gastric varices. Gastroenterol Clin Biol 1994;18:751-760. (Pubitemid 24321762)
20. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003;17:53-64. (Pubitemid 36140434)
21. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008; 48 (Suppl 1) : S68-S92. An excellent synthetic review with the most advances in diagnosis, pathophysiology and treatment of variceal bleeding.
22. Bosch J, Dell'era A. Vasoactive drugs for the treatment of bleeding esophageal varices. Gastroenterol Clin Biol 2004; 28: B186-B189. (Pubitemid 38620719)
23. Dohler KD, Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Pract Res Clin Anaesthesiol 2008;22:335-350. (Pubitemid 351804043)
24. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359. This study reported that association of terlipressin and albumin is more effective than albumin alone in the management of HRS. (Pubitemid 351626950)
25. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385-394.
26. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, doubleblind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368. This first international randomized control study reported the significant improvement in renal function in cirrhotic patients with HRS treated by terlipressin, and showed that improvement in renal function improves overall survival in patients with HRS. (Pubitemid 351615358)
27. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:111-123. (Pubitemid 46109963)
28. Schmid PG, Abboud FM, Wendling MG, et al. Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol 1974;227:998-1004.
29. Garcia-Villalon AL, Garcia JL, Fernandez N, et al. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol 1996;118:1848-1854. (Pubitemid 26252683)
30. Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003;31:215-220. (Pubitemid 36151174)
31. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003;97:1756-1763. (Pubitemid 37475134)
32. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003;95:803-809.
33. Hiltebrand LB, Krejci V, Jakob SM, et al. Effects of vasopressin on microcirculatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock. Anesthesiology 2007;106:1156-1167. (Pubitemid 46828169)
34. Krejci V, Hiltebrand LB, Jakob SM, et al. Vasopressin in septic shock: effects on pancreatic, renal, and hepatic blood flow. Crit Care 2007; 11: R129.
35. Martikainen TJ, Uusaro A, Tenhunen JJ, Ruokonen E. Dobutamine compensates deleterious hemodynamic and metabolic effects of vasopressin in the splanchnic region in endotoxin shock. Acta Anaesthesiol Scand 2004;48:935-943. (Pubitemid 39215224)
36. Sun Q, Dimopoulos G, Nguyen DN, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003;168:481-486. (Pubitemid 37046879)
37. Asfar P, Hauser B, Ivanyi Z, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005;33:373-380. (Pubitemid 40216552)
38. Kopel T, Losser MR, Faivre V, Payen D. Systemic and hepatosplanchnic macro-and microcirculatory dose response to arginine vasopressin in endotoxic rabbits. Intensive Care Med 2008;34:1313-1320. An experimental dose response of vasopressin effects on splanchnic macro and microcirculations. Confirmation of the safety of low-dose vasopressin. (Pubitemid 351904296)
39. Simon F, Giudici R, Scheuerle A, et al. Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial. Crit Care 2009; 13: R113. An experimental study demonstrating the safety for visceral organ function and integrity of low-dose vasopressin when administered as first-line vasopressor in a clinically relevant, long-term model of porcine septic shock characterized by a sustained increase in CO resulting from aggressive fluid resuscitation.
40. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004;32:1327-1331. (Pubitemid 38738588)
41. Knotzer H, Pajk W, Maier S, et al. Arginine vasopressin reduces intestinal oxygen supply and mucosal tissue oxygen tension. Am J Physiol Heart Circ Physiol 2005; 289: H168-H173. (Pubitemid 40934095)
42. Knotzer H, Maier S, Dünser MW, et al. Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model. Intensive Care Med 2006;32:170-174. (Pubitemid 43039394)
43. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catechol amine-treated hyperkinetic septic shock. Intensive Care Med 2004;30:597-604. (Pubitemid 38530094)
44. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-2319. (Pubitemid 36578501)
45. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006;32:1782-1789. (Pubitemid 44607366)
46. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-582. (Pubitemid 34193495)
47. Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646-2650. (Pubitemid 37455414)
48. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125. (Pubitemid 27097820)
49. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699-703.
50. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27:1416-1421.
51. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002;359:1209-1210. (Pubitemid 34304264)
52. Leone M, Albanese J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004;22:314-319. (Pubitemid 39468969)
53. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;28:877-887. The largest multicenter controlled randomized trial comparing vasopressin with norepinephrine in patients with septic shock. The overall mortality was not different between the two arms, and there were no significant differences in terms of side effects or safety. Contrary to all expectation, vasopressin significantly reduced mortality rate in the less severe patients. (Pubitemid 351397087)
54. Nygren A, Thoren A, Ricksten SE. Vasopressin decreases intestinal mucosal perfusion: a clinical study on cardiac surgery patients in vasodilatory shock. Acta Anaesthesiol Scand 2009;53:581-588. A clinical study in eight heterogeneous patients. A confirmation of the risk of microcirculatory hypoperfusion in patients with low CO.
55. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vaso-pressin infusion in septic shock (TERLIVAP) : a randomized, controlled pilot study. Crit Care 2009; 13: R130. The first clinical comparison of hemodynamics and metabolic effects as well as splanchnic hemodynamics between norepinephrine, vasopressin and terlipressin.